Glycobiology · Rare Disease · Regulatory Science · Fractional CSO
Your Scientific Navigator from Discovery to IND
25+ years at the intersection of glycobiology, M6P pathway biology, and rare disease drug development — guiding programs to their True North milestone.
Portfolio & Programs
Strategic Impact
Lysosomal Target Program A
Lysosomal Target Program B
Metabolic Program C
Organizational Relationships
Trusted by Leading Institutions
Logo display requires written permission from each organization
The Virtual C-Suite
A Complete Service — Without the Overhead
Glyko brings together a network of specialized professionals who work as a coordinated team on your program, giving you C-suite caliber coverage at a fraction of the cost.
Colleague Name
Toxicology Expert
Colleague Name
CMC Strategy Specialist
Colleague Name
Bioanalytics Lead
Colleague Name
Regulatory Affairs
What We Do
Three Lanes of Expertise
Vertical 01
Scientific Strategy
From assay development to IND-enabling study oversight, we build the scientific foundation your program needs to move forward with confidence.
- Assay development & optimization
- Nonclinical program design
- IND-enabling study oversight
- Scientific due diligence
- M6P pathway expertise
Vertical 02
Executive Stewardship
Whether you need a fractional CSO or a scientific voice in the boardroom, we bring senior-level guidance without the overhead of a full-time hire.
- Fractional CSO services
- Board advisory roles
- Investor preparation
- Scientific narrative for grants
- Partner and CRO selection
Vertical 03
Regulatory Navigation
We map the regulatory path from early strategy through Pre-IND meetings, Orphan Drug Designation, and FDA submission preparation.
- Pre-IND meeting strategy
- Orphan Drug Designation
- NHP waiver development
- FDA meeting preparation
- Early Phase regulatory plan
The Glyko Brief
Regulatory Intelligence & Perspective
Start the Conversation
Not sure which solution fits your program? Let's navigate together.